Alnylam Data Could Lead To New Gene Silencing Drugs For Neurologic Diseases
Executive Summary
First clinical demonstration of gene silencing in the brain using an RNAi therapeutic could have implications for diseases like Alzheimer’s, ALS and Parkinson’s disease.